TY - JOUR
T1 - Molecular targets in the inhibition of angiogenesis
AU - Dudek, Arkadiusz Z
AU - Pawlak, Wojciethc Z.
AU - Kirstein Pharm, Mark N.
PY - 2003/8
Y1 - 2003/8
N2 - Angiogenesis, the process of blood vessel formation, is crucial for malignant tumour growth and metastases; therefore, it has become an attractive target for anticancer therapy. Theoretically applicable to most solid tumours, this therapy may be advantageous over existing cytotoxic therapy, since it is directed at genetically stable endothelium growing within tumours rather than at malignant cells, which acquire resistance to treatment. Many promising angiogenesis inhibitors have been developed, although their activity has yet to be demonstrated in human clinical trials. To improve therapeutic benefit, this may require further insight into tumour angiogenesis, development of appropriate surrogate markers of activity, treatment of early stage neoplastic disease and probably a combination of different classes of antiangiogenesis agents to overcome redundant mechanisms of angiogenesis control.
AB - Angiogenesis, the process of blood vessel formation, is crucial for malignant tumour growth and metastases; therefore, it has become an attractive target for anticancer therapy. Theoretically applicable to most solid tumours, this therapy may be advantageous over existing cytotoxic therapy, since it is directed at genetically stable endothelium growing within tumours rather than at malignant cells, which acquire resistance to treatment. Many promising angiogenesis inhibitors have been developed, although their activity has yet to be demonstrated in human clinical trials. To improve therapeutic benefit, this may require further insight into tumour angiogenesis, development of appropriate surrogate markers of activity, treatment of early stage neoplastic disease and probably a combination of different classes of antiangiogenesis agents to overcome redundant mechanisms of angiogenesis control.
KW - Antiangiogenic therapy
KW - Tumour angiogenesis
KW - Vascular endothelial growth factor (VEGF)
UR - http://www.scopus.com/inward/record.url?scp=0042329420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042329420&partnerID=8YFLogxK
U2 - 10.1517/14728222.7.4.527
DO - 10.1517/14728222.7.4.527
M3 - Review article
C2 - 12885272
AN - SCOPUS:0042329420
SN - 1472-8222
VL - 7
SP - 527
EP - 541
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
IS - 4
ER -